Emma Hall, PhD, on Bladder Cancer: Results From the BC2001 Trial
2017 Genitourinary Cancers SymposiumEmma Hall, PhD, of the Institute of Cancer Research, London, discusses long-term outcomes with chemoradiotherapy vs radiotherapy alone, and standard vs reduced high-dose volume radiotherapy in muscle-invasive bladder cancer. (Abstract 280)
Related Videos
Toni K. Choueiri, MD, on Urothelial Cancer: Trial Results From Borealis-2
Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, discusses study findings on apatorsen plus docetaxel vs docetaxel alone in platinum-resistant metastatic urothelial cancer. ...
Lawrence H. Einhorn, MD, on Testicular Cancer: The Keynote Lecture
Lawrence H. Einhorn, MD, of the Indiana University Simon Cancer Center, summarizes his keynote lecture on the controversies in management of clinical stage I testicular cancer and the...
Toni K. Choueiri, MD, on Papillary RCC: Phase II Trial Results
Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, discusses a single-arm biomarker-based study of savolitinib in patients with advanced papillary renal cell cancer. (Abstract...
Toni K. Choueiri, MD, on Untreated RCC: Phase II Trial Results
Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, discusses study findings on atezolizumab with or without bevacizumab vs sunitinib in patients with untreated metastatic rena...
W. Marston Linehan, MD, on Renal Cell Carcinoma: Genetic Predisposition
W. Marston Linehan, MD, of the National Cancer Institute, discusses the genetic basis of the different types of kidney cancer, which provides the key to clinical management.
